Teva Pharmaceutical Industries reported $230M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Aerie Pharmaceuticals AERI:US USD 1.65M 12K
ALKERMES ALKS:US USD 3.55M 1.18M
Amgen AMGN:US USD 368M 40M
Biogen BIIB:US USD 59.9M 5.9M
Bristol Myers Squibb BMY:US USD 299M 14M
Eli Lilly And LLY:US USD 81.5M 300K
Endo International Ordinary Shares ENDP:US USD 74.93M 65M
Gilead Sciences GILD:US USD 229M 13M
Henry Schein HSIC:US USD 11M 2M
JAZZ PHA JAZZ:US USD 83.74M 19.86M
Lannett LCI:US USD 15.03M 222K
Novartis NOVN:VX USD 215M 13M
Pacira Pharmaceuticals PCRX:US USD 9.86M 1.02M
Patterson Companies PDCO:US USD 5.56M 870K
Pfizer PFE:US USD 311M 18M
Revance Therapeutics RVNC:US USD 6.92M 3.04M
Teva Pharmaceutical Industries TEVA:US USD 230M 5M
Zoetis ZTS:US USD 53M 0